ArticleHaematologica2013

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Jennifer R Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.